Novartis Psoriasis Drug Tops J and J's StelaraNovartis Psoriasis Drug Tops J and J's Stelara
Novartis said on Friday its experimental psoriasis drug Cosentyx (secukinumab) was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara (ustekinumab). Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2014 Category: Consumer Health News Tags: Dermatology News Source Type: news
Novartis psoriasis drug tops J&J's Stelara in late-stage study
ZURICH (Reuters) - Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara. (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Drug for psoriatic arthritis passes next hurdle with NICE
Draft guidance from the National Institute for Health and Care Excellence has recommended ustekinumab (Stelara) as a treatment option for psoriatic arthritis in certain circumstances. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - December 9, 2014 Category: Nursing Source Type: news
Amgen Psoriasis Drug Brodalumab Tops J and J's UstekinumabAmgen Psoriasis Drug Brodalumab Tops J and J's Ustekinumab
Amgen Inc said on Tuesday that its experimental psoriasis drug, brodalumab, met all the goals of a late-stage study, clearing the rough skin patches associated with the disease more thoroughly than Johnson & Johnson's (ustekinumab) Stelara and a placebo. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2014 Category: Consumer Health News Tags: Dermatology News Source Type: news
Brodalumab Beats Stelara in Psoriasis Trial, Sponsors Say
(MedPage Today) -- More patients achieve total plaque clearance in topline results. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - November 12, 2014 Category: Dermatology Source Type: news
New findings from PSOLAR show persistency difference among biologic therapies
Janssen-Cilag International NV reported new findings at the annual meeting of the European Academy of Dermatology and Venereology (EADV) showing significantly better persistency and lower rates of discontinuation with STELARA® (ustekinumab) therapy in comparison to anti-tumour necrosis factor (TNF)-alpha treatments among patients participating in Psoriasis Longitudinal Assessment and Registry (PSOLAR), a post-marketing registry following patients with moderate to severe plaque psoriasis. (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 13, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Dermatology Rheumatology psoriasis TNF-alpha ustekinumab Source Type: news
New Stelara data in psoriatic arthritis
Data has been released that support the recent label enhancement for Stelara in reducing the rate of progression of structural damage, which represents an important milestone for people living with psoriatic arthritis. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 23, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Dermatology eular Latest News psoriatic arthritis stelara Source Type: news
Crohn’s Disease - United States Drug Forecast and Market Analysis to...
Reportstack new report says that new market players will emerge during the early years of the forecast period - namely, Takeda’s Entyvio in 2014 and J&J’s Stelara in 2015. Their launches will fuel...(PRWeb March 31, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11718051.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 31, 2014 Category: Pharmaceuticals Source Type: news
Novartis begins Phase IIIb trial of secukinumab versus stelara to treat plaque psoriasis
Swiss drug maker Novartis has started enrolling patients in a new Phase IIIb head-to-head trial of IL-17A inhibitor secukinumab (AIN457) versus Stelara (ustekinumab) in moderate-to-severe plaque psoriasis. (Source: Drug Development Technology)
Source: Drug Development Technology - March 25, 2014 Category: Pharmaceuticals Source Type: news
Active Psoriatic Arthritis Yields to Stelara (CME/CE)
(MedPage Today) -- Patients with active psoriatic arthritis -- even those who had previously received a tumor necrosis factor (TNF) inhibitor -- experienced significant benefits with ustekinumab (Stelara) in a multicenter phase III trial. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 12, 2014 Category: Primary Care Source Type: news
Ustekinumab Stops Joint Damage in Psoriatic Arthritis Ustekinumab Stops Joint Damage in Psoriatic Arthritis
In a pooled analysis of data from the PSUMMIT studies, ustekinumab slowed progression of joint damage at week 24, which persisted out to 2 years. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 6, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Inhibition of joint destruction in active psoriatic arthritis
New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA® (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo. Pre-specified integrated analyses from the PSUMMIT I and II trials showed treatment with either STELARA 45 mg or 90 mg resulted in significantly less change from baseline at week 24 in total psoriatic arthritis modified van der Heijde-Sharp (vdH-S) scores compared with placebo... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2013 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news
New STELARA data show inhibition of joint destruction in active psoriatic arthritis
(Tonic Life Communications USA) New findings from two integrated Phase 3 Janssen Research & Development, LLC-sponsored studies showed treatment with STELARA (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo. These results are being presented during the 2013 Annual Meeting of the American College of Rheumatology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 28, 2013 Category: Global & Universal Source Type: news
Stelara OK’d For Psoriatic Arthritis
WebMD Health News
By Kathleen Doheny
Reviewed by Arefa Cassoobhoy, MD, MPH
Oct. 4, 2013 — Stelara, an injectable drug already approved to treat psoriasis, is now also approved to treat psoriatic arthritis.
Psoriatic arthritis is an autoimmune disease. The immune system attacks healthy skin cells and joints, causing inflammation. Of the 7.5 million people with psoriasis, about 10%-30% get psoriatic arthritis.
What Is Stelara?
Stelara works differently from other medications that treat psoriatic arthritis, says Alice Gottlieb, MD, PhD, of Tufts Medical Center. She was the lead researcher on recent Stelara studies. The ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 23, 2013 Category: Consumer Health News Authors: mreal197 Tags: WebMD News Source Type: news
Stelara OK'd for Psoriatic Arthritis
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 8, 2013 Category: Journals (General) Source Type: news
